High dose level:infuse 3.0×10^6 CAR+ T Cells/kg

2 trials

Sponsors

Hebei Yanda Lu Daopei Hospital

Conditions

Refractory/relapsed CD19-positive B-cell leukemiarefractory and relapsed acute B-lymphocytic leukemia

Early Phase 1

Clinical study of CD19 CAR-T cells in the treatment of refractory and relapsed acute B-lymphocytic leukemia

RecruitingChiCTR2000031340

Hebei Yanda Lu Daopei Hospitalrefractory and relapsed acute B-lymphocytic leukemia

Start: 2020-03-30Updated: 2020-04-06

Phase 1

CD19 Chimeric Antigen Receptor T Cells for Treatment of Refractory/Relapsed B Lymphoid Study on the relationship between drug dosage, cell dynamics and curative effect in blood diseases

Active, not recruitingChiCTR2000038532

Hebei Yanda Lu Daopei HospitalRefractory/relapsed CD19-positive B-cell leukemia

Start: 2020-09-25Updated: 2020-11-30

Related Papers

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Blood2022-11-151 citations

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia

eJHaem2022-03-241 citations